Annuncio • Apr 17
Redcare Pharmacy N.V. Announces Board Appointment, Effective April 15, 2026 Redcare Pharmacy N.V. announced that at its Annual General Meeting held on April 15, 2026, the shareholders voted with an absolute majority for all agenda items, including the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. The Supervisory Board now consists of Michael Köhler (Chairman), Peter Schmid von Linstow (Vice-Chairman), Stephan Weber, Anja Hendel and Max Müller. Annuncio • Feb 07
Redcare Pharmacy NV to Report Q2, 2026 Results on Jul 29, 2026 Redcare Pharmacy NV announced that they will report Q2, 2026 results on Jul 29, 2026 Annuncio • Jan 28
Redcare Pharmacy N.V. Supports Seamless Continuation Of Digital E-Prescription Journey With PoPP Draft Specifications Redcare Pharmacy N.V. reported that the national agency responsible for the digitalization of the healthcare system in Germany (gematik) has published the draft specifications of the PoPP (Proof of Patient Presence) module for remote care use case, including the digital redemption of e-prescriptions. PoPP is intended to replace the current VSDM++ patient card verification process on which Redcare’s CardLink solution is based. In its current draft form, the PoPP specifications confirm the continuation of a smooth, low-threshold digital process for e-prescription redemption using Redcare’s Shop Apotheke app in Germany. The ability to verify the eGK and a patient’s insured status without PIN on the app can continue now even more effectively, since an SMS for mobile number verification will no longer be required. Combined with the added optionality of using a digital ID in the future, this ensures stability, more flexibility and supports the continued adoption of digital solutions. The migration to PoPP is part of a broader modernization of Germany’s telematics infrastructure. The new technology raises security standards for data protection while enabling more flexible, software-based authentication options. Beyond enhanced security, this approach is expected to improve accessibility to healthcare services, particularly in remote and digital care settings. Following the publication of the final PoPP specifications for the remote care use case – anticipated in the First Quarter 2026 – Redcare Pharmacy will finalize the technical implementation within its Shop Apotheke app and secure the required regulatory approvals. The official rollout of PoPP Stufe 2 – Online Check-in by gematik is currently planned for the end of 2026. Redcare Pharmacy’s CardLink license extension remains valid until January 31, 2027, providing ample runway for a smooth and well-managed transition. Annuncio • Jan 08
Redcare Pharmacy NV to Report Fiscal Year 2025 Final Results on Mar 04, 2026 Redcare Pharmacy NV announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Mar 04, 2026 Price Target Changed • Jan 07
Price target decreased by 7.5% to €140 Down from €151, the current price target is an average from 8 analysts. New target price is 107% above last closing price of €67.40. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €1.18 next year compared to a net loss per share of €2.27 last year. Annuncio • Oct 07
Redcare Pharmacy NV to Report Q3, 2025 Results on Oct 29, 2025 Redcare Pharmacy NV announced that they will report Q3, 2025 results on Oct 29, 2025 Annuncio • Sep 28
Redcare Pharmacy NV Announces Stepping Down of Jasper Eenhorst from the Management Board Redcare Pharmacy NV announced that Jasper Eenhorst will stepping down from the Managing Board, but will remain with the company until the end of this year to support a smooth transition to his successor. Annuncio • Mar 19
Redcare Pharmacy NV to Report Q2, 2025 Results on Jul 29, 2025 Redcare Pharmacy NV announced that they will report Q2, 2025 results on Jul 29, 2025 Annuncio • Mar 13
Redcare Pharmacy NV Provides Earnings Guidance for 2025 Redcare Pharmacy NV provided earnings guidance for 2025. The company expects Total sales growth in excess of 25%. Annuncio • Mar 11
Redcare Pharmacy NV to Report Q1, 2025 Results on May 06, 2025 Redcare Pharmacy NV announced that they will report Q1, 2025 results on May 06, 2025 Annuncio • Jan 09
Redcare Pharmacy NV to Report Fiscal Year 2024 Final Results on Mar 11, 2025 Redcare Pharmacy NV announced that they will report fiscal year 2024 final results on Mar 11, 2025 Breakeven Date Change • Dec 30
Forecast breakeven date pushed back to 2026 The 12 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 40% per year to 2025. The company is expected to make a profit of €55.9m in 2026. Average annual earnings growth of 62% is required to achieve expected profit on schedule. Reported Earnings • Nov 10
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: €574.5m (up 21% from 3Q 2023). Net loss: €6.91m (down 183% from profit in 3Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Breakeven Date Change • Oct 28
Forecast to breakeven in 2025 The 12 analysts covering Redcare Pharmacy expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €10.2m in 2025. Average annual earnings growth of 54% is required to achieve expected profit on schedule. Annuncio • Oct 04
Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024 Redcare Pharmacy NV revised sales guidance for the full year 2024. The company expected for the full year 2024 that sales will end up slightly higher than predicted at the start of the year, and new guidance is total sales between EUR 2.35 billion and EUR 2.5 billion. Reported Earnings • Jul 31
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: €560.7m (up 34% from 2Q 2023). Net loss: €4.27m (loss narrowed 6.4% from 2Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in Europe. Annuncio • Jul 30
Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG. Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG on mid-May last year.
Redcare Pharmacy NV (XTRA:RDC) completed the acquisition of MediService AG on mid-May last year. New Risk • May 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding). Reported Earnings • Apr 26
First quarter 2024 earnings released First quarter 2024 results: Revenue: €560.2m (up 51% from 1Q 2023). Net loss: €7.81m (loss narrowed 24% from 1Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Europe. Annuncio • Mar 07
Redcare Pharmacy NV Announces Management Departures The Supervisory Board of Redcare Pharmacy NV agreed to the early departure request of the Managing Board members Stephan Weber (CCO) and Marc Fischer (CIO) at the Annual General Meeting on 17 April 2024. This decision comes at an ideal time to transition leadership responsibilities approximately one year before the end of their regular terms of office. This succession plan had been carefully developed and is the result of an extensive evaluation and selection process. Both Stephan Weber and Marc Fischer have agreed with the Supervisory Board to serve Redcare Pharmacy in an advisory capacity until October 2026, provided the relevant agenda item is approved by the Annual General Meeting. New Risk • Mar 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Breakeven Date Change • Mar 07
Forecast breakeven date moved forward to 2024 The 10 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €7.15m in 2024. Earnings growth of 61% is required to achieve expected profit on schedule. Reported Earnings • Mar 06
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: €0.73 loss per share (improved from €4.32 loss in FY 2022). Revenue: €1.80b (up 49% from FY 2022). Net loss: €12.0m (loss narrowed 85% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. Annuncio • Mar 05
Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024 Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024, at 10:00 Central European Standard Time. Agenda: To consider directorate changes. Price Target Changed • Jan 09
Price target increased by 7.6% to €142 Up from €132, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €140. Stock is up 144% over the past year. The company is forecast to post a net loss per share of €0.86 next year compared to a net loss per share of €4.32 last year. Breakeven Date Change • Nov 10
Forecast breakeven date moved forward to 2024 The 11 analysts covering Redcare Pharmacy previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 76% to 2023. The company is expected to make a profit of €229.6k in 2024. Average annual earnings growth of 64% is required to achieve expected profit on schedule. Reported Earnings • Oct 31
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: €475.5m (up 67% from 3Q 2022). Net income: €8.32m (up €28.4m from 3Q 2022). Profit margin: 1.7% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Recent Insider Transactions • Aug 11
CFO & Member of Management Board recently sold €1.0m worth of stock On the 7th of August, Jasper F. Eenhorst sold around 9k shares on-market at roughly €112 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jasper F. has been a net seller over the last 12 months, reducing personal holdings by €992k. New Risk • Aug 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Significant insider selling over the past 3 months (€454k sold). Reported Earnings • Aug 02
Second quarter 2023 earnings released: €0.24 loss per share (vs €1.37 loss in 2Q 2022) Second quarter 2023 results: €0.24 loss per share (improved from €1.37 loss in 2Q 2022). Revenue: €419.9m (up 46% from 2Q 2022). Net loss: €4.56m (loss narrowed 82% from 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. New Risk • Jun 22
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €65m Forecast net loss in 2 years: €3.3m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€3.3m net loss in 2 years). Significant insider selling over the past 3 months (€785k sold). Price Target Changed • Jun 08
Price target increased by 8.1% to €101 Up from €93.00, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €96.06. Stock is up 7.1% over the past year. The company is forecast to post a net loss per share of €1.87 next year compared to a net loss per share of €4.32 last year. Price Target Changed • May 23
Price target increased by 7.5% to €99.08 Up from €92.17, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of €97.98. Stock is up 15% over the past year. The company is forecast to post a net loss per share of €2.97 next year compared to a net loss per share of €4.32 last year. Recent Insider Transactions • May 12
Co-Founder recently sold €454k worth of stock On the 5th of May, Marc Fischer sold around 5k shares on-market at roughly €90.80 per share. This transaction amounted to 3.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Marc's only on-market trade for the last 12 months. Breakeven Date Change • May 05
Forecast to breakeven in 2025 The 9 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €15.8m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule. Reported Earnings • May 03
First quarter 2023 earnings released First quarter 2023 results: €0.56 loss per share. Revenue: €372.1m (up 22% from 1Q 2022). Net loss: €10.2m (loss narrowed 55% from 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Consumer Retailing industry in Europe. Breakeven Date Change • Apr 11
Forecast to breakeven in 2025 The 13 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €7.44m in 2025. Average annual earnings growth of 63% is required to achieve expected profit on schedule. Recent Insider Transactions • Apr 05
COO & Member of the Managing Board recently sold €331k worth of stock On the 30th of March, Theresa Holler sold around 4k shares on-market at roughly €78.85 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.4m more than they bought in the last 12 months. Reported Earnings • Mar 09
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: €4.32 loss per share (further deteriorated from €4.15 loss in FY 2021). Revenue: €1.20b (up 14% from FY 2021). Net loss: €77.6m (loss widened 4.7% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Breakeven Date Change • Mar 08
No longer forecast to breakeven The 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €26.3m in 2025. New consensus forecast suggests the company will make a loss of €377.1k in 2025. Recent Insider Transactions • Jan 31
COO & Member of the Managing Board recently sold €149k worth of stock On the 24th of January, Theresa Holler sold around 2k shares on-market at roughly €64.72 per share. This transaction amounted to 1.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Theresa has been a net seller over the last 12 months, reducing personal holdings by €260k. Buying Opportunity • Jan 05
Now 22% undervalued Over the last 90 days, the stock is up 26%. The fair value is estimated to be €66.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 40% in 2 years. Earnings is forecast to grow by 78% in the next 2 years. Price Target Changed • Jan 05
Price target decreased to €84.43 Down from €92.00, the current price target is an average from 14 analysts. New target price is 63% above last closing price of €51.68. Stock is down 51% over the past year. The company is forecast to post a net loss per share of €4.02 next year compared to a net loss per share of €4.15 last year. Breakeven Date Change • Dec 31
Forecast to breakeven in 2025 The 13 analysts covering Shop Apotheke Europe expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €26.3m in 2025. Average annual earnings growth of 55% is required to achieve expected profit on schedule. Recent Insider Transactions • Dec 22
Chairman of the Managing Board & CEO recently bought €85k worth of stock On the 16th of December, Stefan Feltens bought around 2k shares on-market at roughly €42.58 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months. Price Target Changed • Nov 10
Price target decreased to €91.64 Down from €98.79, the current price target is an average from 14 analysts. New target price is 106% above last closing price of €44.43. Stock is down 70% over the past year. The company is forecast to post a net loss per share of €3.69 next year compared to a net loss per share of €4.15 last year. Reported Earnings • Nov 03
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: €284.5m (up 20% from 3Q 2021). Net loss: €20.1m (loss widened 37% from 3Q 2021). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Consumer Retailing industry in Europe. Price Target Changed • Oct 27
Price target decreased to €98.79 Down from €115, the current price target is an average from 14 analysts. New target price is 126% above last closing price of €43.64. Stock is down 68% over the past year. The company is forecast to post a net loss per share of €3.72 next year compared to a net loss per share of €4.15 last year. Recent Insider Transactions • Aug 28
Co-Founder recently sold €972k worth of stock On the 23rd of August, Stephan Weber sold around 15k shares on-market at roughly €67.03 per share. In the last 3 months, there was an even bigger sale from another insider worth €1.5m. Stephan has been a seller over the last 12 months, reducing personal holdings by €1.9m. Breakeven Date Change • Aug 06
No longer forecast to breakeven The 11 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.03m in 2024. New consensus forecast suggests the company will make a loss of €2.04m in 2024. Reported Earnings • Aug 05
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: €287.2m (up 15% from 2Q 2021). Net loss: €24.8m (loss widened 122% from 2Q 2021). Over the next year, revenue is forecast to grow 26%, compared to a 8.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings. Recent Insider Transactions • Jun 19
COO & Member of the Managing Board recently sold €1.5m worth of stock On the 15th of June, Theresa Holler sold around 18k shares on-market at roughly €82.68 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €3.1m more than they bought in the last 12 months. Recent Insider Transactions • Jun 10
Co-Founder recently sold €953k worth of stock On the 2nd of June, Stephan Weber sold around 10k shares on-market at roughly €95.33 per share. This was the largest sale by an insider in the last 3 months. This was Stephan's only on-market trade for the last 12 months. Breakeven Date Change • May 09
No longer forecast to breakeven The 11 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.54m in 2024. New consensus forecast suggests the company will make a loss of €1.32m in 2024. Reported Earnings • May 08
First quarter 2022 earnings: Revenues in line with analyst expectations First quarter 2022 results: Revenue: €304.8m (up 7.3% from 1Q 2021). Net loss: €22.9m (loss widened 296% from 1Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 25%, compared to a 7.6% growth forecast for the industry in Germany. Breakeven Date Change • Apr 22
No longer forecast to breakeven The 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.54m in 2024. New consensus forecast suggests the company will make a loss of €1.93m in 2024. Breakeven Date Change • Apr 09
No longer forecast to breakeven The 12 analysts covering Shop Apotheke Europe no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €9.14m in 2024. New consensus forecast suggests the company will make a loss of €1.32m in 2024. Recent Insider Transactions • Mar 10
Co-Founder recently sold €916k worth of stock On the 4th of March, Marc Fischer sold around 13k shares on-market at roughly €73.30 per share. This was the largest sale by an insider in the last 3 months. This was Marc's only on-market trade for the last 12 months. Breakeven Date Change • Mar 05
Forecast breakeven date pushed back to 2024 The 13 analysts covering Shop Apotheke Europe previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 99% per year to 2023. The company is expected to make a profit of €12.5m in 2024. Average annual earnings growth of 85% is required to achieve expected profit on schedule. Reported Earnings • Mar 04
Full year 2021 earnings: Revenues in line with analyst expectations Full year 2021 results: Revenue: €1.06b (up 9.5% from FY 2020). Net loss: €74.2m (loss widened 342% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 21%, compared to a 8.3% growth forecast for the retail industry in Germany. Price Target Changed • Mar 04
Price target decreased to €150 Down from €163, the current price target is an average from 13 analysts. New target price is 93% above last closing price of €77.95. Stock is down 56% over the past year. Breakeven Date Change • Mar 03
Forecast breakeven date pushed back to 2024 The 6 analysts covering Shop Apotheke Europe previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of €33.7m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Reported Earnings • Nov 03
Third quarter 2021 earnings released The company reported a poor third quarter result with increased losses and weaker control over costs, although revenues were flat. Third quarter 2021 results: Revenue: €237.9m (flat on 3Q 2020). Net loss: €14.7m (loss widened 240% from 3Q 2020). Breakeven Date Change • Aug 10
Forecast breakeven pushed back to 2023 The 9 analysts covering Shop Apotheke Europe previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 68% per year to 2022. The company is expected to make a profit of €24.7m in 2023. Average annual earnings growth of 121% is required to achieve expected profit on schedule. Reported Earnings • Aug 08
Second quarter 2021 earnings released The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: €250.4m (up 7.6% from 2Q 2020). Net loss: €11.2m (loss widened €11.0m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Jul 15
Price target decreased to €202 Down from €221, the current price target is an average from 9 analysts. New target price is 52% above last closing price of €133. Stock is up 9.6% over the past year. Breakeven Date Change • Jun 16
Forecast breakeven pushed back to 2022 The 9 analysts covering Shop Apotheke Europe previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 98% to 2021. The company is expected to make a profit of €17.4m in 2022. Average annual earnings growth of 102% is required to achieve expected profit on schedule. Reported Earnings • May 08
First quarter 2021 earnings released The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: €284.1m (up 22% from 1Q 2020). Net loss: €5.79m (loss widened 17% from 1Q 2020). Executive Departure • Apr 30
Chairman of the Supervisory Board Jan Pyttel has left the company On the 21st of April, Jan Pyttel's tenure in the role of Chairman of the Supervisory Board ended. We don't have any record of a personal shareholding under Jan's name. Jan is the only executive to leave the company over the last 12 months. Recent Insider Transactions • Mar 14
Chairman of the Managing Board & CEO recently bought €96k worth of stock On the 8th of March, Stefan Feltens bought around 550 shares on-market at roughly €175 per share. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months. Reported Earnings • Mar 05
Full year 2020 earnings released: €1.17 loss per share (vs €2.78 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €968.1m (up 38% from FY 2019). Net loss: €16.8m (loss narrowed 54% from FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Mar 05
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 0.2%. Earnings per share (EPS) also surpassed analyst estimates by 48%. Over the next year, revenue is forecast to grow 23%, compared to a 54% growth forecast for the Online Retail industry in Germany. Is New 90 Day High Low • Feb 03
New 90-day high: €210 The company is up 29% from its price of €162 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 25% over the same period. Is New 90 Day High Low • Jan 13
New 90-day high: €165 The company is up 4.0% from its price of €159 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 21% over the same period. Analyst Estimate Surprise Post Earnings • Nov 20
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 26%, compared to a 46% growth forecast for the Online Retail industry in Germany. Analyst Estimate Surprise Post Earnings • Nov 09
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 25%, compared to a 47% growth forecast for the Online Retail industry in Germany. Is New 90 Day High Low • Nov 08
New 90-day high: €164 The company is up 20% from its price of €137 on 10 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.